Randy Dockens
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms, Cholinesterase and Neurodegenerative Diseases, Analytical Methods in Pharmaceuticals
Most-Cited Works
- → Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease(2012)363 cited
- → Targeting Prodromal Alzheimer Disease With Avagacestat(2015)230 cited
- → Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder(2010)171 cited
- → Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?(2009)114 cited
- → Anticonvulsant activity of some 4-aminobenzamides(1984)80 cited
- → Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers(2012)65 cited
- → Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat(2012)63 cited
- → Coadministration of Nefazodone and Benzodiazepines(1995)61 cited
- → Pharmacokinetics and Tolerability of Buspirone during Oral Administration to Children and Adolescents with Anxiety Disorder and Normal Healthy Adults(2001)48 cited
- → A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects(2012)47 cited